BrainCool AB (publ) has completed the recruitment in the Nordic clinical study with Cooral® System to prevent oral mucositis (OM)
The recruitment to the Nordic study to prevent oral mucositis is now completed. The study is a controlled, randomized Nordic study of 180 patients treated with powerful cytostatic therapy due to malignant blood disorders. In the study, BrainCool's product Cooral® System was evaluated to prevent troublesome mucosal damage in the oral cavity and pharynx (oral mucositis, OM). “The completed recruitment is an important milestone for BrainCool and Cooral® System. I am extremely grateful for the team's hard work at the clinics”- says Martin Waleij, CEO of BrainCool AB. The analysis of the
